...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: OUCH!!! Things Move Faster In The Cancer Arena and Other Gems

Yes, we paid something for Zenith shares. The property that ZEL has in trials now had belonged to RVX and was handed over. That is payment. Yes, Zenith has developed it farther but it had been taken far enough by RVX to realize their was value and reason to develop it. If RVX hadn't felt this, they would not have split the company. Giving up some of their property made RVX's assets worth less. You try to figure out how much as the market had no way to value that at that time. Resverlogix stated this back then.

"based on the relative estimated fair market values of the New Resverlogix Common Shares and the Zenith Common Shares immediately after the share exchange, is as follows:"

"Resverlogix New Common Shares    90.9%"

"Zenith Common Shares                    9.1%

RVX was stating that there was an asset transfer from RVX to Zenith which would lower the value of the RVX shares, hence a payment for your Zenith shares. Immediate market reaction is not a measure of this payment as the market had no way to measure the value of what was transferred.

Share
New Message
Please login to post a reply